home All News open_in_new Full Article

VIH : qui pourra se payer le nouveau traitement révolutionnaire ?

L'Europe autorise la commercialisation du lenacapavir, un traitement preventif contre le virus du sida. Mais son prix, 28 000 dollars par patient et par an, cree la polemique.


today 1 week ago attach_file Science

attach_file Sport
attach_file Events
attach_file Science
attach_file Science
attach_file Events
attach_file Science
attach_file Sport
attach_file Politics
attach_file Science
attach_file Science
attach_file Society
attach_file Politics
attach_file Science
attach_file Science
attach_file Science
attach_file Society
attach_file Events
attach_file Science
attach_file Science
attach_file Economics


ID: 1917748022
Add Watch Country

arrow_drop_down